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consisting of several subpopulations within tumors. CSCs display the malignant phenotype,
self-renewal ability, altered genomic stability, specific epigenetic signature, and most of the
time can be phenotyped by cell surface markers (e.g., CD133, CD24, and CD44). Numerous
studies support the concept that non-stem cancer cells (non-CSCs) are sensitive to cancer ther-
apy while CSCs are relatively resistant to treatment. In glioblastoma stem cells (GSCs), there is
clonal heterogeneity at the genetic level with distinct tumorigenic potential, and defined GSC
marker expression resulting from clonal evolution which is likely to influence disease progres-
sion and response to treatment. Another level of complexity in glioblastoma multiforme (GBM)
tumors is the dynamic equilibrium between GSCs and differentiated non-GSCs, and the poten-
tial for non-GSCs to revert (dedifferentiate) to GSCs due to epigenetic alteration which confers
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Glioblastoma stem cells (GSCs) plasticity 153GBM cells to therapeutic doses of temozolomide (TMZ) or ionizing radiation (IR) increases the
GSC pool both in vitro and in vivo. This review describes various subtypes of GBM, discusses the
evolution of CSC models and epigenetic plasticity, as well as interconversion between GSCs and
differentiated non-GSCs, and offers strategies to potentially eliminate GSCs.
Copyright ª 2015, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Glioblastoma multiforme (GBM) comprises the largest group
of brain tumors which respond very poorly to current
therapies.1 In the United States, approximately 13,000
people die annually from GBM, and it is disappointing that
only about 10% of patients survive 5 years.2e4 The combi-
nation of radiotherapy and adjunct temozolomide (TMZ)
has increased the survival of patients with GBM, but the
median survival of GBM patients is only about 14.6 months.5
The highly aggressive nature of GBM is due to multiple ge-
netic alterations which result in augmented cytoprotective
and survival pathways as well as numerous defects in the
apoptotic signaling machinery and epigenetic alterations
(Fig. 1).
A growing body of evidence indicates that rare pop-
ulations of cancer cells, termed cancer stem cells (CSCs) or
cancer initiating cells (CICs), play a significant role in
several cancers, including GBM.6e8 GBM tumors display high
degree of phenotypic, cellular, genetic, and epigenetic
heterogeneity, and it is believed that a major problem in
the unresponsiveness of GBM tumors to therapy is the ex-
istence of GBM stem cells (GSCs) within the tumor which
are most crucial for driving invasive tumor growth and
relapse.6,9 Emerging results have revealed that in GBM and
other malignancies, CSC enrichment may occur either from
an increased symmetric self-renewal division rate of CSCs
or a reprogramming of non-CSC to CSCs and conferring
phenotypic plasticity to the tumor population.10 The
concept of interconversion of CSCs and non-CSCs has pro-
vided major complexity in understanding the role of CSCs in
tumor heterogeneity, a potential mechanism for thera-
peutic relapse, resistance to anticancer therapies, and
developing therapeutic strategies. In this review we
describe various subtypes of GBM, discuss the evolution of
CSC models and epigenetic plasticity as well as intercon-
version between GSCs and differentiated non-GSCs, and
offer strategies to potentially eliminate GSCs. Under-
standing GBM tumor cell plasticity and its underlying mo-
lecular mechanisms will help in the design of more
effective therapies against GBM and preventing tumor
recurrence.
Glioblastoma multiforme (GBM)
GBM comprises the most common and very aggressive form
of primary brain tumors which respond very poorly to the
current therapies.1,2 This most malignant brain tumor is
designated as World Health Organization (WHO) grade IV
astrocytoma which expresses the astrocyte marker, glialfibrillary acidic protein (GFAP).11e14 Initiation and recur-
rence of primary GBM may be caused by a subpopulation of
GSCs which may derive from mutated neural stem and
precursor cells.8e14 GBM tumors developed from lower-
grade astrocytomas or oligodendrogliomas are termed sec-
ondary GBMs (Fig. 1). While primary and secondary GBM’s
are histologically similar, they are genetically different.15,16
Primary GBM frequently displays molecular alterations in
EGFR, PDGFRA, PTEN, p53 tumor suppressor protein, NF1,
CDKN2A/B, and telomerase reverse transcriptase (TERT)
promoter mutations (see Fig. 1).16,17 Furthermore, as re-
ported by Cadieux et al, global hypomethylation is
frequently observed in primary human GBM.18
Primary GBM is heterogeneous in nature, and based on
its patterns of gene expression and genetic changes, four
different subtypes including proneural, neural, classical
and mesenchymal have been identified.19,20 While the
biological significance and origin of these GBM subtypes are
unclear, patients with specific GBM subtypes exhibit
distinct survival times and different responses to ther-
apy.12,19,20 A high frequency of isocitrate dehydrogenase 1
(IDH1) mutations and O6-methylguanine-DNA methyl-
transferase (MGMT) promoter methylation among young
adult patients with primary GBM compared to other sub-
types correlates with increased survival.21 The classical
subtype is associated with a high frequency of EGFR aber-
rations and low expression of p53 tumor suppressor protein
mutations.22 The mesenchymal subtype displays loss of the
tumor suppressor gene NF1 with high CD44 and MERTK
expression, and the neural subtype does not express any
particular alterations of specific genes or pathways.12,22
The most complete information has been provided by
The Cancer Genome Atlas (TCGA) Research Network which
published a report by analysis of copy number, methylation
patterns, expression profiling, and whole-genome
sequencing of GBM samples.20 Many genes including EGFR,
PDGFRA, CDK4, MDM2, MDM4, MET, CDK6, N-Myc, Cyclin D2,
PIK3CA, and AKT3 have been found amplified in GBM,
further contributing to the complexity in developing ther-
apies to treat GBM.20 Moreover, significant abnormalities in
several signaling pathways including the receptor tyrosine
kinase pathway, the p53 pathway, and the RB pathway
were found.12,16,20Cancer stem cell model
GBM tumors display a great degree of phenotypic and
functional heterogeneity.7,8,12,13 Heterogeneity among
tumor cells arises within a single tumor as a result of genetic
and epigenetic changes (Fig. 2) as well as different
Figure 1 Genetic alterations and aberrant signaling pathways in primary and secondary GBM. A. The continued growth and
recurrence of primary GBM is due to the presence of GSCs which express various protein markers and display self-renewal and
tumorigenic potential. Modified from Masui et al.15 B. Epigenetic changes in GBM. Numerous molecular alterations shown in this
figure and described in the text occur in primary GBM. Mutations in p53 tumor suppressor protein (p53) and ATRX typically occur in
low-grade gliomas and secondary GBM. Mutation of the IDH1 gene is commonly found in low-grade gliomas and secondary GBM, but
is rare in primary GBM. Mutation of IDH1 leads to aberrant DNA methylation and mutations in the important chromatin modifier
ATRX, affecting chromatin structure. Figure was modified from Kondo et al.16
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The genetic alterations and epigenetic changes of the cells
within the same tumor is not well characterized, and for
future personalized medicine strategies, it is necessary to
explore intratumoral heterogeneity with respect to the
phenotype and genotype of the tumor as well as evaluating
its epigenetic alterations to achieve effective treatment forGBM.25,26 To better understand intratumoral heterogeneity
in a given GBM tumor, Sottoriva et al demonstrated that
investigating genome-wide GBM intratumoral genomic het-
erogeneity can be used to reveal tumor evolution.25
Furthermore, the authors showed that based on gene
expression levels, tumor fragments from different anatom-
ical regions of the same patient tumor may be classified into
Figure 3 Multiple signaling networks in GSCs. A complex
and integrated signaling network governs self-renewal, stem-
ness, and maintaince of CSCs including GSCs. As shown in this
figure, this network of proteins belong to many pivotal cellular
pathways and include several plasma membrane receptors,
cytoplasmic signaling proteins, specific transcription factors,
growth factors, and ligands.
Figure 2 Relationship between neuronal stem cells, dif-
ferentiation, GSCs, cancer initiation, and dedifferentiation.
NSCs are able to differentiate into neural progenitors. Neural
progenitors differentiate into neurons and glial progenitors
differentiate to oligodendrocytes, ependymal cells, and as-
trocytes. GBM is initiated from the transformation of NSCs into
GSCs. Similarly, glial progenitors are able to trigger tumor
development following malignant transformation of normal
progenitor cells. Astrocytes, neurons, oligodendrocytes, and
ependymal cells also have the potential to initiate
tumorigenesis.33
Glioblastoma stem cells (GSCs) plasticity 155different GBM subtypes.25 Significantly, by using single-
molecule techniques, the authors described the clonal
composition of single tumor fragments and showed that a
hierarchy of mitotic clones coexists within the same frag-
ment of tumor. These impressive results unraveled the
complexity of GBM tumors with respect to their heteroge-
neity which represents the signature of GBM clonal evolution
at the single patient level.25 These results demonstrate the
urgent need for personalized medicine and the difficulty in
developing effective therapies for each GBM patient.
The origin of tumor cell heterogeneity may occur from
clonal evolution and from differentiation of CSCs.7,27e32 The
CSC model well explains the versatility and plasticity of
heterogeneous tumor populations. This model discusses how
very small subpopulations of CSCs drive cancer progression
and how small subpopulations of cancer cell types with
specific features are produced within a given tumor.26 CSCs
are characterized by their ability to generate xenografts
representing the initial tumor in immunodeficient animals
and to divide asymmetrically to allow self-renewal as well as
differentiation into a non-CSC population (Fig. 3). However,
recent experimental evidence showing CSC plasticity sug-
gests that the tumor cell populations are dynamic, and both
CSCs and non-CSCs are capable of interconversion (Figs. 3
and 4) due to environmental factors.7,8,33e39 The dediffer-
entiation of non-CSCs to CSCs further complicates the gen-
eration of tumor heterogeneity and CSC-targeted
therapy.39,40 As stated by Vries et al, any tumor cell can
revert to a CSC after gaining a clonal advantage over the
original CSC during its development.28 While much evidence
supports the CSC model in several cancers, reliability on cell
surface markers for identifying authentic CSCs is limited.
However, clonal analysis and lineage tracing demonstratingthe hierarchical organization of tumors in vivo provide
strong evidence in support of the CSC concept.41,42 In sup-
port of this CSC concept, Cheng et al by in vivo cell lineage
tracing also showed that GSCs contribute to vascular peri-
cytes that may remodel perivascular niches.43
The relationship between neuronal stem cells (NSCs) and
GSCs as well as differentiation of these stem cells are
shown in Fig. 2. GSCs like other CSCs are a rare population
of slow growing cells in tumors which display various
“stemness” properties including (1) the ability to self-
renew and differentiate into distinct lineages through
different intermediate progenitors, (2) co-existence or
heterogeneity of cells with different differentiation ca-
pacities providing the cellular hierarchy within the tumor,
and (3) GSCs have the ability to initiate tumors in intra-
cranial xenograft models in immunodeficient animals that
recapitulate phenotypic characteristics of the initial tumor
including tumor cell heterogeneity, invasiveness, migration
and metastasis, tumor hypoxic response; resistance to
drugs and radiation; resistance of tumors to apoptosis
stimuli, and vascular characteristics.2,6e8,44,45 Mounting
evidence shows that the stem cell niche, i.e., the envi-
ronment in which GSCs reside, is responsible for the
maintenance of these cells with respect to “stemness” and
therapeutic response.36,46e48 The intimate network of
various cell types and niche paracrine factors are respon-
sible for controlling the necessary signaling pathways that
regulate the properties of GSCs. As shown in Fig. 3,
numerous signaling pathways maintain stemness and regu-
late the tumor propagating capacity of CSCs including GSCs.
GSC specific markers
The role of the cell surface protein CD133 (pronin) as a
cancer stem cell marker in GBM has been extensively
investigated. While the CD133 identifies GSCs that form
Figure 4 MicroRNAs identified in GSCs. A summary of deregulated microRNAs regulating various cellular processes is listed. This
is summary of the previously reported publications cited in the reference list.16,64,96,97,130
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transplanted in immune-compromised mice, CD133-
negative cells displaying similar properties have also been
reported.49e54 Interestingly, Brescia et al through clonal
analysis reported that actually there is not a hierarchical
relation between CD133-positive and CD133-negative cells,
and in fact CD133 is capable of changing its subcellular
localization between the cytoplasm and the plasma mem-
brane of GSC neurospheres.49 Significantly, these authors
demonstrated that silencing CD133 in human GBM neuro-
spheres using lentivirus-mediated short hairpin RNA
impaired the self-renewal and tumorigenic capacity of
neurosphere cells. Interestingly, hypoxia significantly
increased the percentage of CD133-positive cells from 69%
to 92%.55 These data collectively suggest that CD133 is
indispensible for GSC function and essential for maintaining
the self-renewal and tumorigenic potential of GBM stem
cells.55 Moreover, Denysenko et al demonstrated that
CD133-positive cell lines showed increased proliferation
rates in neurospheres and increased differentiation poten-
tial towards neuronal lineages, while cell lines with low
CD133 expression showed mesenchymal properties
in vitro.56 Moreover, other factors may collaborate with
CD133 and increase the stemness of GSCs. For instance,
EGFRvIII contributes to stemness through coexpression with
CD133.57 Moreover, while other biomarkers have been
investigated in GBM including L1CAM, SOX2, CXCR4, Integrin
a-6, and CD36, their roles in GSCs are not well defined.57
While tumor heterogeneity is evident in all four clinically
relevant subtypes of GBM as described above, molecular
signaling in GSCs in individual subtypes is poorly character-
ized.58 In light of this, Mao et al recently identified andcharacterized two mutually exclusive GSC subtypes, pro-
neural (PN) and mesenchymal (Mes) GSCs.58 Mes GSCs
showed more aggressive phenotypes both in vitro and in
intracranial xenografts of GBM in mice, and were very
resistant to radiation compared with PN GSCs. Interestingly,
both the glycolytic pathway and ALDH1A3 activities were
robustly elevated in Mes but not PN GSCs, and inhibition of
ALDH1A3 attenuated the growth of Mes but not PN GSCs.
Recent results clearly show the heterogeneity of GSCs that
display intrinsically distinct tumorigenic ability. By combining
ploidy-based flow sorting with array-comparative genomic
hybridization, Stieber et al found that primary GBMs are
either mono- or polygenomic tumors (64% versus 36%,
respectively) within primary GBMs.26 The authors showed
that monogenomic tumors are composed of a pseudodiploid
tumor clone and normal stromal cells, whereas polygenomic
tumors consisted ofmultiple tumor clones and always contain
a pseudodiploid subpopulation. While multiple tumor GSC
clones could generate spheroids as well as spheroid-based
xenografts, genetically distinct clones had different tumori-
genic potential. Interestingly, genetically distinct tumor cell
populations displayed putative GSCmarkers including CD133,
CD15 (SSEA-1), A2B5, and CD44. Therefore, the clonal het-
erogeneity at the genetic level, tumorigenic potential, and
GSC marker expression may influence GBM progression and
govern its response to treatment.26GBM heterogeneity and GSC plasticity
Recent research efforts have been directed toward selec-
tively targeting CSCs for therapy.29 However, therapeutic
Glioblastoma stem cells (GSCs) plasticity 157response is influenced by the stemness of a tumor which is
defined by cancer genetics, epigenetics, microenviron-
ment, and dedifferentiation or conversion of non-CSCs to
CSCs (Fig. 2).7,8,59e63 These processes determine stemness
and resistance to drugs and ionizing radiation in GBM tu-
mors. Moreover, growing evidence reveals a high degree of
plasticity of cancer cells with the ability to effectively and
reversibly transit between differentiated and CSC pheno-
types in response to microenvironmental factors like
hypoxia.62e67 Therefore, the capacity of tumor cells to
mutually interconvert is directed by genetic, epigenetic,
and microenvironmental regulation by which tumor cells
alter their phenotypic and functional role which contrib-
utes to tumor growth.62e67 A new model explaining the
differential ability of tumor cells to interconvert explains
the concept of “CSC plasticity” in which many cells within
the tumor can serve as stem cells with various degrees of
“stemness” regulated by microenvironmental factors.68,69
Indeed, Chaffer et al demonstrated that CSC cells can
arise de novo from more differentiated cell types and that
hierarchical models of stem cell biology achieve bidirec-
tional interconversion between stem and non-stem com-
partments (Fig. 2).68
It has been demonstrated that GSCs can be more resis-
tant to conventional anticancer agents like TMZ than their
differentiated GBM cells.70,71 Conversely, other reports
have shown that primary GSCs are sensitive to TMZ therapy,
and significant expansion of different GSC subpopulations
after treatment of GBM patients with TMZ has been
detected.37,72,73 It has been reported that the chemo-
resistance of GSCs correlated with elevated levels of the
detoxifying protein MGMT, which confers strong intrinsic
resistance to these cells, and that extrinsic factors and
conversion of non-CSCs to new CSCs contributes to the
resistance of CSC to TMZ.74e76 To understand GBM post-
therapy, Auffinger et al recently investigated the proper-
ties of GSCs after primary chemotherapy with TMZ.37 These
authors first showed that exposure of patient-derived as
well as established GBM cell lines to therapeutic doses of
TMZ increases the GSC pool over time both in vitro and
in vivo. Secondly, by performing lineage-tracing analysis of
the expanded GSC pool, they showed that such increase by
TMZ was the result of a phenotypic shift in the non-GSC
population to a GSC-like state which expressed pluripo-
tency and stemness markers such as CD133, SOX2, Oct4,
and Nestin. Moreover, these new GSCs served as a reservoir
for initiating relapse of the tumors.37 The phenomenon of
spontaneous conversion of a non-CSC population into a CSC-
like population has also been reported in breast cancer.61
Therefore, collectively, these results plus published data
on other tumors indicate that the tight cellular hierarchy
within a tumor (i.e., the initial CSC hypothesis) does not
control CSCs, and the cellular heterogeneity of the tumor
plus cellular plasticity control the stemness of CSCs
including GSCs.37,61,77,78
The identification of GSCs has advanced our knowledge
of the molecular mechanisms involved in regulating GBM
development. However, the specific intrinsic factors that
govern GSCs self-renewal, stemness, differentiation, and
dedifferentiation of GBM tumor cells to GSCs are not un-
derstood.7,8,37,79 Moreover, emerging evidence has
revealed that specific GBM microenvironments (niches) alsoplay a crucial role in maintaining the stemness of GSCs, and
that changes in the niches may lead to these processes in
GSCs.47,80,81 Delineating the molecular mechanisms by
which cellular plasticity is influenced by niche factors can
govern the interconversion of non-CSCs to CSCs and
enhance the “stemness” of the tumor. This information
should provide an important direction for developing
potentially effective therapies and therapeutic strategies
for targeting the heterogeneous GSC subpopulations as well
as the bulk of the tumor population with the aim of erad-
icating GBM.Transcription factors and GCSs
The cellular epigenetic state of an organism (or “epi-
genome”) incorporates a landscape of complex and flexible
molecular events that create dynamic plasticity in response
to environmental cues, and enables cells to function under
different conditions with phenotypic and functional versa-
tility within cell populations having identical genetic
backgrounds.82e84 This morphological and functional flexi-
bility or plasticity is particularly important for CSCs which
generate tumor cells that transiently expand and then un-
dergo differentiation to form the bulk of the tumor.60,85
However, the underlying molecular mechanisms operating
this tumor cell plasticity is not clear. Interestingly, using
combinatorial mapping of various epigenetic markers and
gene expression results from GSCs, Suva` et al recently
identified a core set of four neurodevelopmental tran-
scription factors (TFs) including POU3F2, SOX2, SALL2, and
OLIG2 essential for GBM propagation.86 Significantly, more
than 50% of the cells with all four TF (4 TF) also expressed
the CSC marker CD133 compared to 4 TF-negative cells,
which lack CD133. These TFs coordinately bind and activate
stem-like tumor propagating cell (TPC)-specific regulatory
elements. Interestingly, they are sufficient and essential to
totally reprogram differentiated GBM cells and interconvert
these cells to TPCs.86 These exciting results revealed that
these 4TFs are able to reproduce the epigenetic charac-
teristic and phenotype of native or initial TPCs. Moreover,
by reconstructing the transcriptional network controlled by
these factors, Suva` et al highlighted critical interactions
and a regulatory role for a chromatin-modifying complex
involving RCOR2 and LSD1.86 These significant findings
identified the RCOR2/LSD1 histone demethylase complex as
a candidate therapeutic target in human GBM stem-like
TPCs.86 These data establish the epigenetic basis of plas-
ticity and evolutionary and developmental hierarchies
within GBM.86
Another critical transcription factor playing an impor-
tant role in the GSC phenotype is FOXM1, a master regulator
of mitotic progression of cancer cells. FOXM1 forms a pro-
tein complex with the mitotic kinase maternal embryonic
leucine zipper kinase (MELK) in GSCs, leading to phos-
phorylation and activation of FOXM1.87 Activated FOXM1
results in increased mitotic regulatory genes in GSCs. TMZ
treatment enriches both FOXM1- and MELK- positive GSCs,
and adding Siomycin A, a CSC-targeted agent, to TMZ
treatment in mice harboring GSC-derived intracranial tu-
mors enhanced the effects of TMZ.87 Identifying and
developing therapeutic agents to inhibit TFs has been very
158 A.R. Safa et al.complex. Since the protein complex of FOXM1 with the
mitotic kinase MELK in GSCs plays a critical role in GSC
maintenance, a specific MELK inhibitor, OTSSP167, has been
shown to have in vitro and in vivo effects on various human
cancer xenograft models and is a promising agent for GBM
therapy.88 Moreover, Minata et al used the multi-kinase
inhibitor C1 and showed that it induces mitotic catastro-
phe in GBMs, primarily through MELK kinase inhibition.89
To further understand the regulation of GSC sub-
populations, Chudnovsky et al recently identified a 397-kDa
transcription factor, ZFHX4, which regulates differentia-
tion, and its suppression increased GBM-free survival in
intracranial xenografts.90 The authors showed that ZFHX4
interacts with CHD4, a core member of the NuRD (nucleo-
some remodeling and deacetylase) complex. Furthermore,
using expression data derived from GBM patients, they
found that ZFHX4 is a regulatory factor that links the
chromatin remodeling NuRD complex and the GBM tumor
initiating cells (TIC) or GSC state.Epigenetic regulation of GSCs
Known mechanisms of epigenetic gene regulation include
(1) chromatin remodeling and histone modification, (2) DNA
methylation, (3) regulation by polycomb group proteins
(PcGs), and (4) control and regulation by microRNAs (miR-
NAs). Chromatin remodeling and histone modification re-
sults in histone acetylation and phosphorylation,
ubiquitination, sumoylation, and ADP-ribosylation. DNA
methylation results in covalent modification of cytosine
nucleotides at the C5 position of particular areas of
unmethylated CpG dinucleotides.91 PcGs play crucial roles
in regulating many cellular processes including develop-
ment, pluripotency, senescence, and cancer.92 PcGs are
essential epigenetic factors and some members have his-
tone methyltransferase activity.91,93MicroRNAs and other epigenetic factors in
GBCs
miRNAs are non-coding regulatory RNAs that are dysregu-
lated in GSCs, suggesting they play an important role in
posttranscriptional gene regulation and function in a vari-
ety of cellular processes.94 Recent results have revealed
that miRNAs play important regulatory roles in the GSC
apoptotic pathway, differentiation, proliferation, migra-
tion and invasion, drug resistance, and radiation resis-
tance.94,95 Like CSCs from other types of cancer, GSCs are
controlled by specific receptor signaling and the regulation
of stem cell genes by transcription factors and miRNAs.
Recently, a number of new targets for these regulators for
GBM treatment have been identified (Fig. 4) and demon-
strated that miRNA expression patterns are correlated with
the developmental lineage and differentiation state of
tumor cells, as well as innovative biomarkers.94e100 Several
published articles have summarized a wide range of miRNAs
in GSCs and the molecular mechanisms of miRNAs involved
in the signaling pathways regulating these processes, as
well as potential usefulness of miRNAs for eliminating GSCs
(Fig. 4).96,101e103 From the viewpoint of the CSC hypothesis,several deregulated miRNAs have been strongly implicated
in regulating the GSCs self-renewal capacity, maintenance
of stemness and plasticity, and resistance to drugs and ra-
diation therapy, as well as unresponsiveness to apoptotic
stimuli (Fig. 4).8,103e107 Therefore, miRNAs can serve as
potential targets for anti-GSC therapeutics.103,108e110
Godlewski et al demonstrated a link between miR-128,
which is significantly downregulated in GBM, and the loss of
GSC self-renewal, which occurs by direct regulation of the
neural stem cell (NSC) self-renewal factor B lymphoma Mo-
MLV insertion region 1 homolog (BMI1).110 The polycomb
repressor complex (PRC) is an epigenetic regulator of
transcription and its action is mediated by two protein
complexes, PRC1 and PRC2. PRC functions as an oncogene
in GBM where it is involved in GSC maintenance and radi-
oresistance.111 miR-128 directly targets the mRNA of
SUZ12, an important component of PRC2, in addition to
BMI1, a component of PRC1.111 This reduction of SUZ12
expression blocks the partially redundant functions of
PRC1/PRC2, thereby significantly reducing PRC activity and
its associated histone modifications.
Epigenetic modifications regulate intratumoral hetero-
geneity, which is usually regulated by specific GSC niches,
particularly, perivascular and hypoxic region microenvi-
ronments.112 Moreover, GSC survival, proliferation, and
maintenance is regulated by oncogenic cytoprotective
signaling pathways and epigenetic modifications (Fig. 3).113
Recently, Nabilsi et al investigated the extent to which
epigenetic differences contribute to intratumoral cellular
heterogeneity by developing a high-throughput method,
termed MAPit-patch.113 The authors found several differ-
entially expressed and methylated promoters that are
associated with altered gene expression between NSC and
GBM cell populations. In addition, considering each pro-
moter individually, substantial epigenetic heterogeneity
was observed across the sequenced molecules, indicating
the presence of epigenetically distinct cellular sub-
populations within a GBM tumor.113 Their results showed
the biological relevance of epigenetically distinct sub-
populations to the phenotypic heterogeneity of tumor cell
populations. Moreover, Schonberg et al demonstrated that
changes in chromatin accessibility without alterations in
DNA methylation may comprise a novel class of epigenetic
biomarkers of GBM.112 A summary of the significance and
targets of GSC miRNAs is shown in Fig. 4.
While the underlying mechanisms of GSC plasticity are
not well established, as discussed above, it is regulated by
interconversion of GBM tumor cells to GSCs. Mechanisti-
cally, Natsume et al have shown that this conversion is
accompanied by the gain or loss of polycomb repressive
complex 2 (PRC2), which modifies chromatin structure.114
PRC2 mediates lysine-27 trimethylation on histone H3 and
affects pluripotency or development-associated genes
(e.g., Nanog, Wnt1, and BMP5) in GSCs as well as alterations
in the subcellular localization of EZH2, a catalytic compo-
nent of PRC2. Mechanistic studies revealed that epigenetic
regulation by PRC2 is a key mediator of tumor cell plas-
ticity, which is required for the adaptation of GBM cells to
their microenvironment.114
Transcriptional mechanisms that control the phenotypic
conversion of differentiated tumor cells into tumor-
propagating stem-like cells remain to be found. Lopez-
Glioblastoma stem cells (GSCs) plasticity 159Bertoni recently showed that the reprogramming tran-
scription factors Oct4 and Sox2 trigger GBM cells to change
into stem-like and tumor-propagating cells via a mechanism
involving direct DNA methyltransferase (DNMT) promoter
transactivation, leading to global DNA methylation and
DNMT-dependent downregulation of multiple miRNAs.115
They showed that one of the miRNAs, miRNA-148a, inhibi-
ted GBM cell stem-like properties and tumor-propagating
potential. These findings identify methylation- and
microRNA-based strategies for inhibiting the GSCs, their
functions, and contributions to tumor growth and
recurrence.115
Epigenetic therapy
The identification and development of drugs to correct
aberrant epigenetic processes in CSCs requires an in depth
understanding of the extent and roles of epigenetic
reprogramming in these cells. Among many alterations,
amplification and rearrangements of the epidermal growth
factor receptor (EGFR) gene are frequently found in GBM.
The most common variant is EGFR variant III (EGFRvIII) and
this variant could be a marker for GSCs showing that
epigenetic mechanisms have a role in maintaining hetero-
geneous EGFRvIII expression.116 Demethylation induced a
20%e60% increase in the percentage of EGFRvIII-positive
cells, indicating that some cells could re-express EGFRvIII.
Interestingly, inhibition of histone deacetylation resulted in
a 50%e80% reduction in EGFRvIII expression.116
Two main features of cancer are aberrant gene function
and altered patterns of gene expression, and evidence
shows that epigenetic changes in collaboration with genetic
alterations cause dysregulation in cancer.117,118 However,
the epigenetic changes in cancer are potentially reversible,
and treating CSCs with demethylating agents or HDAC in-
hibitors may potentially reactivate silenced tumor sup-
pressor and TF genes.118 The DNA methyltransferase
(DNMT) inhibitor 5-azacytidine is an effective anticancer
agent and inhibitor of GSCs.119e121 Another class of epige-
netic inhibitors are HDAC inhibitors. HDACs are a family of
18 deacetylating enzymes that remove acetyl groups from
lysine residues of histone proteins and other proteins
including TFs.122 HDACs regulate the conformation and
activity of chromatin and mostly function as transcriptional
co-repressors as part of large multi-protein complexes.122
HDAC inhibitors and DNA damaging agents synergistically
inhibit the growth and induce apoptosis in GSC cells
possibly because they promote an open chromatin confor-
mation and allow more effective access of DNA damaging
agents to the chromatin, resulting in the increased effec-
tiveness of these agents.12
Clinical significance of GSC plasticity
For the future of personalized medicine for cancer pa-
tients, delineating the molecular mechanisms to predict
the therapeutic response in GBM is critically important. A
major challenge is to identify molecular predictors of
response to new drugs. However, in the absence of such
detailed molecular mechanisms, it is still possible to some
degree to predict the response of GBM tumors to therapy.For example, in GBM cells TMZ is cytotoxic to cells by
triggering DNA damage, but it can be rapidly repaired by
the protein MGMT. In a subset of GBM, the MGMT promoter
methylation, impairs the repair mechanism and confers
chemosensitivity.123 While numerous GSC targeted thera-
pies have been identified, the usefulness of these com-
pounds from the viewpoint of pharmacokinetics and
toxicity profiles and whether they cross the bloodebrain
barrier (BBB) remain to be found. Repurposing FDA-
approved drugs which are clinically used for other dis-
eases may identify effective agents for GBM therapy. For
example, several drugs that target epigenetic alterations,
including HDAC inhibitors and DNA methyltransferase
(DNMT), approved for hematological malignancies, are
available for solid tumor therapy.124 Recently, Jiang et al
used GBM cells and GSCs to identify several FDA-approved
compounds that potentially could be useful in GBM treat-
ment.125 Their findings provided the basis for the rational
combination of statins and topoisomerase inhibitors for
GBM therapy. Moreover, using high-throughput chemical
screens, Hothi et al identified an FDA-approved agent for
the treatment of alcoholism, disulfiram (DSF), as an inhib-
itor of human GSCs.126 Interestingly, DSF is a relatively non-
toxic drug that can cross the BBB, and it is a direct and
potent inhibitor of human MGMT in brain tumor cells.126,127
These results support the repurposing of DSF for GBM
therapy.127 Another group of agents potentially useful for
GBM therapy are epigenetic inhibitors. For example,
treating GSCs with the histone deacetylase inhibitors
trichostatin A (TSA) and valproic acid (VPA) significantly
reduced proliferation rates, decreased the expression of
stem cell markers, and induced differentiation of these
cells.128 Using these agents may increase the efficacy of
conventional cancer treatments for eliminating GSCs.
Moreover, it has been shown that GBM patients have dis-
played stable disease and partial responses to the redox
agent perylene-quinone hypericin (HYP), a compound tar-
geting multiple epigenetic mechanisms.129Future directions
While considerable progress has been made toward
isolating GSCs, it is still not clear what the molecular
characteristics of authentic GSCs are. Therefore, identi-
fying the specific and reliable biomarkers of GSCs is critical.
Current studies have shown the presence of distinct sub-
populations of GSCs within a single GBM tumor. Therefore,
it would be critically important to develop therapeutic
strategies that contain agents targeting different signaling
pathways and/or employing effective multi-targeting
agents to eradicate these GSCs which display several
phenotypic, genotypic and epigenetic characteristics.
Mounting evidence supports a model of tumorigenicity with
considerable plasticity between the non-GSC and GSC
subpopulations within a GBM tumor, and particularly
interconversion of the differentiated non-GSCs to GSCs
upon chemotherapy treatment. Investigating specific niche
factors which influence the interconversion between GSCs
and non-GSCs will provide significant information on the
role of microenvironment on GSC plasticity. Moreover, un-
derstanding the molecular mechanisms of how cellular
160 A.R. Safa et al.plasticity can govern the interconversion of non-CSCs to
CSCs and enhance the “stemness” of the tumor is required
for developing effective therapeutic strategies to treat
GBM. Targeting the mechanisms associated with drug-and
ionizing radiations (IR)-induced dedifferentiation and plas-
ticity may potentially lead to the development of rational
therapeutic strategies for treatment of GBM.
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